Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bipulendu Jena

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Blood|May 5, 2010
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptorBipulendu Jena, Gianpietro Dotti, Laurence J N Cooper
Blood|March 24, 2012
Good T cells for bad B cellsLaurence J N Cooper, Bipulendu Jena, Catherine M Bollard
Current Hematologic Malignancy Reports|February 4, 2014
Driving CAR-based T-cell therapy to successBipulendu Jena, Judy S Moyes, Helen Huls, et al.
Current Hematologic Malignancy Reports|December 11, 2012
CARs in chronic lymphocytic leukemia -- ready to driveChitra Hosing, Partow Kebriaei, William Wierda, et al.
Plos One|March 8, 2013
Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trialsBipulendu Jena, Sourindra Maiti, Helen Huls, et al.
Frontiers in Bioscience (Scholar Edition)|December 29, 2011
Chimeric antibody receptors (CARs): driving T-cell specificity to enhance anti-tumor immunityPartow Kebriaei, Susan S Kelly, Pallavi Manuri, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 10, 2014
Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric antigen receptor independent of specificityDavid Rushworth, Bipulendu Jena, Simon Olivares, et al.
Human Gene Therapy|November 24, 2011
Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignanciesPartow Kebriaei, Helen Huls, Bipulendu Jena, et al.
The Journal of Clinical Investigation|May 17, 2016
CD62L+ NKT cells have prolonged persistence and antitumor activity in vivoGengwen Tian, Amy N Courtney, Bipulendu Jena, et al.
Plos One|June 7, 2013
Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cellsHarjeet Singh, Matthew J Figliola, Margaret J Dawson, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Blood|May 5, 2010
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptorBipulendu Jena, Gianpietro Dotti, Laurence J N Cooper
Blood|March 24, 2012
Good T cells for bad B cellsLaurence J N Cooper, Bipulendu Jena, Catherine M Bollard
Current Hematologic Malignancy Reports|February 4, 2014
Driving CAR-based T-cell therapy to successBipulendu Jena, Judy S Moyes, Helen Huls, et al.
Current Hematologic Malignancy Reports|December 11, 2012
CARs in chronic lymphocytic leukemia -- ready to driveChitra Hosing, Partow Kebriaei, William Wierda, et al.
Plos One|March 8, 2013
Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trialsBipulendu Jena, Sourindra Maiti, Helen Huls, et al.
Frontiers in Bioscience (Scholar Edition)|December 29, 2011
Chimeric antibody receptors (CARs): driving T-cell specificity to enhance anti-tumor immunityPartow Kebriaei, Susan S Kelly, Pallavi Manuri, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 10, 2014
Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric antigen receptor independent of specificityDavid Rushworth, Bipulendu Jena, Simon Olivares, et al.
Human Gene Therapy|November 24, 2011
Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignanciesPartow Kebriaei, Helen Huls, Bipulendu Jena, et al.
The Journal of Clinical Investigation|May 17, 2016
CD62L+ NKT cells have prolonged persistence and antitumor activity in vivoGengwen Tian, Amy N Courtney, Bipulendu Jena, et al.
Plos One|June 7, 2013
Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cellsHarjeet Singh, Matthew J Figliola, Margaret J Dawson, et al.
Pageof 2